Table 1.
Patient Demographic and Disease Data
| Gender, N (%) | |
| Women | 4 (19) |
| Men | 17 (81) |
| Age (years) | |
| Median [min-max] | 63 [50–82] |
| Main psoriasis type, N (%) | |
| Plaque type | 20 (95) |
| Palmoplantar Pustular | 1 (5) |
| Severity score prior to treatment, Mean±SD | |
| PASI | 16.6 (8) |
| PGA | 3,6 (0,85) |
| BSA | 29 (15) |
| Prior systemic treatment, N (%) | 18 (86) |
| Phototherapy | 11 (52) |
| Methotrexate | 13 (61) |
| Cyclosporine | 2 (10) |
| Acitretine | 12 (57) |
| Etretinate | 1 (5) |
| BT type administered, N (%) | |
| Etanercept | 7 (33) |
| Infliximab | 2 (10) |
| Adalimumab | 2 (10) |
| Ustekinumab | 7 (33) |
| Secukinumab | 4 (19) |
| Ixekizumab | 1 (5) |
| Guselkumab | 1 (5) |
| APR, No (%) | 10 (48) |
| Type of malign HM, N (%) | |
| Non-Hodgkin’s lymphoma | 5 (24) |
| Hodgkin’s lymphoma | 4 (19) |
| Chronic lymphoid leukemia | 5 (24) |
| Multiple myeloma | 1 (5) |
| Waldenström disease | 1 (5) |
| Vaquez disease | 3 (14) |
| Essential thrombocythemia | 2 (10) |
| Delay between diagnosis and start of PT/APR treatment, Median [min-max] (months) | 53 [0–204] |
Abbreviations: APR, apremilast; BT, biological treatment; HM, hematological malignancy; PASI, psoriasis area severity index; PGA, psoriasis global assessment; BSA, body surface area.